ERBB2 Regulates MED24 during Cancer Progression in Mice with Pten and Smad4 Deletion in the Pulmonary Epithelium

ERBB2 is an oncogenic driver with frequent gene mutations and amplification in human lung tumors and is an attractive target for lung cancer therapy. However, target therapies can be improved by understanding the in vivo mechanisms regulated by ERBB2 during lung tumor development. Here, we generated genetic mouse models to show that Erbb2 loss inhibited lung tumor development induced by deletion of Pten and Smad4. Transcriptome analysis showed that Erbb2 loss suppressed the significant changes of most of the induced genes by ablation of Pten and Smad4. Overlapping with ERBB2-associated human lung cancer genes further identified those ERBB2 downstream players potentially conserved in human and mouse lung tumors. Furthermore, MED24 was identified as a crucial oncogenic target of ERBB2 in lung tumor development. Taken together, ERBB2 is required for the dysregulation of cancer-related genes, such as MED24, during lung tumor development.

[1]  C. Creighton,et al.  JNK1/2 represses Lkb1-deficiency-induced lung squamous cell carcinoma progression , 2019, Nature Communications.

[2]  S. Durinck,et al.  Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations. , 2018, Cancer cell.

[3]  Roy S. Herbst,et al.  The biology and management of non-small cell lung cancer , 2018, Nature.

[4]  H. Ji,et al.  Targeting HER2 Aberrations in Non–Small Cell Lung Cancer with Osimertinib , 2018, Clinical Cancer Research.

[5]  J. Soutourina.  Transcription regulation by the Mediator complex , 2017, Nature Reviews Molecular Cell Biology.

[6]  S. Sigismund,et al.  Emerging functions of the EGFR in cancer , 2017, Molecular oncology.

[7]  I. Wistuba,et al.  Mig-6 deficiency cooperates with oncogenic Kras to promote mouse lung tumorigenesis. , 2017, Lung cancer.

[8]  P. Wee,et al.  Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways , 2017, Cancers.

[9]  M. Jackson,et al.  FAM83 proteins: Fostering new interactions to drive oncogenic signaling and therapeutic resistance , 2016, Oncotarget.

[10]  Jianqiang Mao,et al.  ErbB2 Pathway Activation upon Smad4 Loss Promotes Lung Tumor Growth and Metastasis , 2015, Cell reports.

[11]  A. Eisen,et al.  Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline. , 2014, Current oncology.

[12]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[13]  Sean M. Hartig,et al.  The Epidermal Growth Factor Receptor Critically Regulates Endometrial Function during Early Pregnancy , 2014, PLoS genetics.

[14]  Rocky Cipriano,et al.  Conserved Oncogenic Behavior of the FAM83 Family Regulates MAPK Signaling in Human Cancer , 2014, Molecular Cancer Research.

[15]  Gang Wang,et al.  The Mediator complex: a master coordinator of transcription and cell lineage development , 2014, Development.

[16]  M. Mehta,et al.  Molecular profiling in non-small cell lung cancer: a step toward personalized medicine. , 2013, Archives of pathology & laboratory medicine.

[17]  H. Greulich,et al.  Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment , 2013, Front. Oncol..

[18]  H. Ji,et al.  Selective requirement for Mediator MED23 in Ras-active lung cancer , 2012, Proceedings of the National Academy of Sciences.

[19]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.

[20]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[21]  T. Mukohara,et al.  Mediator Subunits MED1 and MED24 Cooperatively Contribute to Pubertal Mammary Gland Development and Growth of Breast Carcinoma Cells , 2012, Molecular and Cellular Biology.

[22]  Moorthy P Ponnusamy,et al.  Targeting the EGFR signaling pathway in cancer therapy , 2012, Expert opinion on therapeutic targets.

[23]  Linda J Pike,et al.  Mechanics of EGF Receptor/ErbB2 kinase activation revealed by luciferase fragment complementation imaging , 2011, Proceedings of the National Academy of Sciences.

[24]  Iver Petersen,et al.  The morphological and molecular diagnosis of lung cancer. , 2011, Deutsches Arzteblatt international.

[25]  Mei Sun,et al.  MED19 promotes proliferation and tumorigenesis of lung cancer , 2011, Molecular and Cellular Biochemistry.

[26]  Shanlou Qiao,et al.  REGγ modulates p53 activity by regulating its cellular localization , 2010, Journal of Cell Science.

[27]  S. Horvath,et al.  Elevated MED28 expression predicts poor outcome in women with breast cancer , 2010, BMC Cancer.

[28]  M. Meyerson,et al.  HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy , 2009, Proceedings of the National Academy of Sciences.

[29]  János Szöllosi,et al.  Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. , 2005, Experimental cell research.

[30]  R. Darnell,et al.  The TRAP100 component of the TRAP/Mediator complex is essential in broad transcriptional events and development , 2002, The EMBO journal.

[31]  V. Keshamouni,et al.  Mechanism of 17-β-Estradiol-induced Erk1/2 Activation in Breast Cancer Cells , 2002, The Journal of Biological Chemistry.

[32]  Monilola A. Olayioye,et al.  Update on HER-2 as a target for cancer therapy: Intracellular signaling pathways of ErbB2/HER-2 and family members , 2001, Breast Cancer Research.

[33]  K. Lackey,et al.  The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. , 2001, Cancer research.

[34]  A. Jemal,et al.  Lung Cancer Statistics. , 2016, Advances in experimental medicine and biology.

[35]  V. Keshamouni,et al.  Mechanism of 17-beta-estradiol-induced Erk1/2 activation in breast cancer cells. A role for HER2 AND PKC-delta. , 2002, The Journal of biological chemistry.